磁共振引导聚焦超声中央外侧丘脑毁损术治疗慢性难治性神经病理性疼痛:63次干预的回顾性长期随访分析
该单中心非随机回顾性横断面分析纳入55例患者共63次MRgFUS中央外侧丘脑毁损术,平均随访55个月,平均疼痛缓解42%±37%,61%病例疼痛缓解≥30%,51%患者疼痛缓解≥50%,仅记录1例严重不良事件(上唇麻木),作者认为该方法是安全的且结果随时间稳定。
要点
- MRgFUS CLT术后3个月、1年及末次随访平均疼痛缓解分别为42%±32%、43%±36%、42%±37%。
- 疼痛缓解≥50%的患者比例在3个月、1年、末次随访分别为54%、49%、51%。
- 记录1例严重不良事件(上唇麻木),异位痛在68%患者中减轻或消失,无新发异位痛。
核心结论
- 作者认为MRgFUS CLT治疗神经病理性疼痛是安全的方法,且结果随时间稳定。
研究设计与样本
- 单中心、非随机回顾性横断面分析,连续纳入55例患者,共进行63次MRgFUS CLT干预,平均随访55个月。
主要发现
- 平均疼痛缓解在3个月为42%±32%、1年为43%±36%、末次随访为42%±37%(n=63)。
- 疼痛缓解≥30%的病例比例在3个月为65%、1年为63%、末次随访为61%。
- 良好结局(疼痛缓解≥50%)在3个月为54%、1年为49%、末次随访为51%。
- 1年随访时平均VAS评分降低百分比与疼痛缓解相似:持续痛降低41%,疼痛发作降低49%。
- 疼痛发作平均频率降低92%,异位痛在68%患者中减轻或消失,MRgFUS CLT后无新发异位痛。
关键数值与推荐
- 疼痛缓解≥30%的病例比例:3个月65%、1年63%、末次随访61%。
- 良好结局(疼痛缓解≥50%)患者比例:3个月54%、1年49%、末次随访51%。
- 平均疼痛缓解:3个月42%±32%、1年43%±36%、末次随访42%±37%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Medial thalamotomies were introduced in the late 1940s. Pain relief was shown to be achieved for all body locations. With some exceptions, these early relatively small series showed frequent, more or less complete recurrence of the original pain. The posterior part of the central lateral nucleus in the human medial thalamus was identified in the 1990s using multiarchitectonic studies and intraoperative single-cell recordings and was confirmed as a surgical target. This retrospective patient series extended over 11 years. Its goal was to demonstrate the efficacy and risk profile of the MR-guided focused ultrasound (MRgFUS) central lateral thalamotomy (CLT) against chronic and therapy-resistant neuropathic (i.e., neurogenic) pain. METHODS: In this single-center, nonrandomized retrospective cross-sectional analysis of consecutive patients, 63 consecutive MRgFUS CLT interventions were performed in 55 patients. RESULTS: The mean follow-up duration was 55 months. A total of 112 CLT targets were performed, and the CLT was applied bilaterally in 48 patients and contralateral to their pain in 7 patients. Repeat MRgFUS interventions were performed in 8 patients. One serious adverse event with numbness of the upper lip was recorded. The mean pain relief rated by patients was 42% ± 32% at 3 months, 43% ± 36% at 1 year, and 42% ± 37% at the last follow-up (n = 63). The proportions of cases with ≥ 30% pain relief were 65% at 3 months, 63% at 1 year, and 61% at the last follow-up. Good outcomes (≥ 50% pain relief) were found in 54% of patients at 3 months, 49% at 1 year, and 51% at the last follow-up. The reduction in mean VAS scores showed similar percentage reductions as those for pain relief (-41% for continuous pain and -49% for pain attacks) at the 1-year follow-up. The mean frequency of pain attacks was reduced by 92%. Allodynia was reduced or suppressed in 68% of patients and never appeared de novo after MRgFUS CLT. CONCLUSIONS: These results suggest that MRgFUS CLT against neuropathic pain is a safe approach and its results are stable over time. At a mean follow-up duration of 55 months, the mean pain relief was 42% and more than 50% of patients still reported ≥ 50% pain relief. Patients with classical and idiopathic trigeminal neuralgia reported a higher mean pain relief compared with the whole patient group.
引用
- Gallay MN, Magara AE, Moser D, et al. Magnetic resonance-guided focused ultrasound central lateral thalamotomy against chronic and therapy-resistant neuropathic pain: retrospective long-term follow-up analysis of 63 interventions. J Neurosurg. 2023. PMID: 36840733. doi:10.3171/2023.1.JNS222879
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。